Blog

Big news on the legal front! The U.S. District Court for Northern Alabama has just ruled that the Federal Corporate Transparency Act (“CTA”) is unconstitutional.  This ruling came as a result of a lawsuit by  National Small Business United, a trade group of over

We are delighted to report a new recognition for Nariman Farvardin, President of Stevens Institute of Technology. He is to be awarded the Ellis Island Medal of Honor. This award is intended to recognize individuals who have made it their mission

Artificial intelligence systems will be the savior of mankind! Artificial intelligence systems will doom mankind! Which statement is true?? Who knows at this point? But one thing is certain, this new powerful technology will have a tremendous impact on the

The BioNJ 31st Annual Dinner Meeting and Innovation Celebration, held on February 8, 2024, was a significant event that showcased the vibrant life sciences industry in New Jersey. Under the theme “Toasting New Jersey’s Amazing Life Sciences Industry,” this gathering

Sometimes a technical innovation fails to deliver improved patient outcomes. An example may be robotic-assisted knee replacements. Robotic-assisted knee replacements, especially using Stryker’s Mako system, have become increasingly common in the U.S. This surge in robotic surgeries signifies a major

Did you know that the Federal government could be your “partner” in ownership of your patent rights? That could happen if your patented technology resulted from research sponsored by a government grant. The National Institute of Standards and Technology (“NIST”) recently released

Stage2Startups has a wonderful focus. It seeks to help “mature” entrepreneurs who have had a lot of “life experience” start new businesses. I had an opportunity to present to many mature startup entrepreneurs on a Stage2Startups webinar on issues that are

I’m happy to send congratulations to my friend and colleague, Lisa Policare, CEO of Penn Wealth Planning on being recognized in the 2024 Forbes Best-in-State Wealth Management Teams list.  The list, compiled by Shook Research based on hundreds of interviews,

Small privately-held companies will have new compliance burdens starting in the new year. The Federal Corporate Transparency Act (“CTA”) will require substantial disclosures of company and personal information and updates of that information with severe penalties for non-compliance.  The following summary

Bio NJ has some tremendous opportunities for C-suite executives at life sciences companies. Bio NJ has established a networking and discussion group exclusively for founders and C-Suite executives of life sciences companies.  It provides leaders of those companies with opportunities to

Here’s a great opportunity for those interested in biomedical research and entrepreneurship. The Biomedical Engineering Department at Stevens Institute of Technology in Hoboken, NJ is hosting its BME Day event on Friday, February 2, on its beautiful campus.  The event will feature a keynote

Orphan drug development is a crucial and complex area of pharmaceutical research. It’s dedicated to creating treatments for rare diseases. These drugs are designated as ‘orphan’ because, without government assistance, the pharmaceutical industry has little financial incentive to develop treatments.  The

Losing one’s sight is one of the cruelest types of disabilities.  We depend on that sense for so much of what we do. So, it’s always encouraging to see advances that limit or eliminate causes of severe vision loss and/or

A significant new reporting requirement started on January 1, 2024. The Federal Corporate Transparency Act requires that most small limited liability companies and corporations must disclose the beneficial owners of equity interests in those entities. Failure to comply can result

I’m sending congratulations to my friends and fellow lawyers, Ralph Selitto and John Kim. Both are experienced intellectual property lawyers who have just joined the international legal powerhouse Clark Hill.  Ralph and John will be working in the Clark Hill

The realm of medical devices has seen remarkable advancements in 2023. Innovators need to be aware of these advancements to assess the opportunities they provide for making healthcare more efficient, more effective and more patient-centric. Let’s explore three of these

Key Highlights: ·        Strategic Shift: CRISPR Therapeutics is pivoting from cancer drug development to cell-based medicines for autoimmune diseases. ·         Potent Alternatives: The company focuses on advancing two newer, more potent cell therapy candidates, with lupus

It’s not just your hometown physician’s travel bag anymore! In the dynamic field of life sciences, cell and gene therapy have emerged as revolutionary forces.  It redefines our approach to treating complex diseases. This blog post delves into the latest advancements

One of the features that excites me about representing life sciences and other technology innovators is the impact they can have on our society.  I enjoy using the skills I learned in over 30 years of working with business leaders

We live in an extraordinary time. It’s a time where technology in life sciences is peeling back the curtain on the underlying causes of disease. In this note, I’ll cover recent developments in gene editing therapies: Crowley Law LLC is

Stevens Institute of Technology (“Stevens”) has announced some great results impacting cancer therapies. In this note, I’ll describe Crowley Law is delighted to be supporting innovators in the life sciences and other technology areas.  If you are a life sciences or

Halloween may be over – but frightening developments can still abound. The availability of funds for digital healthcare companies has contracted significantly since the halcyon days of 2020 and 2021.  The market has seen All of these developments have heightened